Wolfe Research on Regeneron Pharma (REGN): 'Results were good'

Regeneron (REGN) Still Has 'Significant Upside' - Morgan Stanley

Morgan Stanley analyst Matthew Harrison upgraded shares of Regeneron (NASDAQ: REGN) to Overweight from Equal-Weight, raising the firm's price target on the stock to $851 from $625 in a note to investors on Friday.

The upgrade is on the back of news Regeneron's Eylea drug met two... More

JPMorgan on Regeneron Pharma (REGN): '8mg afibercept represents a step forward for the Eylea franchise'

JPMorgan analyst Chris Schott reiterated a Neutral on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "This morning, Regeneron announced its highly anticipated data for highdose Eylea and we wanted to share some thoughts. Overall, the data suggests 8mg afibercept represents an important extension of the Eylea franchise that offers both the potential to extend a portion of the Eylea franchise beyond 2024 as well as blunt some of the competitive pressures from Roches Vabysmo. Specifically, high-dose Eylea showed noninferiority at both the 12 and 16 wk dosing... More

Regeneron (REGN) Eylea News Removes a 'Key Overhang' says Analyst

Regeneron (NASDAQ: REGN) shares jumped over 20% after the company said on Thursday that its anti-blindness treatment Eylea, jointly developed with Bayer, has met primary endpoints in two key trials.

Two late-stage trials demonstrated that Eylea, which is usually given in doses of two milligrams every... More

Regeneron Pharma (REGN) PT Raised to $796 at Goldman Sachs

Goldman Sachs analyst Salveen Richter raised the price target on Regeneron Pharma (NASDAQ: REGN) to $796.00 (from $790.00) while maintaining a Buy rating.

The analyst comments "REGN announced that the primary endpoints were met in the pivotal PULSAR and PHOTON trials in wet age-related macular degeneration (wAMD) and diabetic macular edema... More

Regeneron (REGN) Says Dupixent Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented detailed positive results from the second of two Phase 3 trials (PRIME) evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis in a late-breaking session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress. These data, which were consistent with the detailed data from the first Phase 3 trial (PRIME2) in prurigo nodularis, show Dupixent... More

Regeneron Pharma (REGN) PT Raised to $790 at Truist Securities; High-Dose Eylea Data Removes Key Overhang

Truist Securities analyst Robyn Karnauskas raised the price target on Regeneron Pharma (NASDAQ: REGN) to $790.00 (from $718.00) while maintaining a Buy rating, saying high-dose Eylea could fend off competition.

The analyst commented, "We see a key overhang removed with results... More

Morgan Stanley 'Encouraged' on Regeneron Pharma (REGN)

Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $625.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Majority of patients maintained out to 12-/16-wks: Mgt. reported that both pivotal Ph3trials testinghigh dose Eylea (8 mg) with 12- and... More

RBC Capital Comments on on Regeneron Pharma (REGN) Primary Endpoint Data

RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating and $628.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Overall we believe the data do likely support approvability and some degree of market conversion to high dose Eylea, with evidence that... More

Regeneron Pharma (REGN) PT Raised to $760 at Evercore ISI

Evercore ISI analyst Dr. Josh Schimmer raised the price target on Regeneron Pharma (NASDAQ: REGN) to $760.00 (from $635.00) while maintaining a Outperform rating.

The analyst comments "The high dose Eylea data announced this morning was surprisingly good 90% of DME patients and ~80%... More

Regeneron Pharma (REGN) 'High-Dose Eylea Data Far Exceeds Expectations, Supporting Franchise' - BMO

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $788.00 price target on Regeneron Pharma (NASDAQ: REGN) after both High-dose Eylea trials, Pulsar and Photon hit on primary end points.

The analyst commented, "91%/89% of DME patients an 79%/77% were initiated and maintain on 12- and... More

Regeneron (REGN) to Resume Trading at 9:50 a.m.

Regeneron (NASDAQ: REGN) to Resume Trading at 9:50 a.m.

Regeneron (REGN) announces Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The PHOTON trial in DME and the PULSAR trial in wAMD both demonstrated that aflibercept 8 mg 12- and 16-week dosing regimens achieved non-inferiority in vision gains compared to the EYLEA 8-week... More

Regeneron (REGN) Halted, News Pending

Regeneron (NASDAQ: REGN) Halted, News Pending